Streptonigrin (Bruneomycin) is an orally active antibiotic and pan-PAD inhibitor, inhibiting PAD1, PAD2, PAD3 and PAD4 with IC50 of 48.3 µM, 26.1 µM, 0.43 µM and 2.5 µM, respectively. Streptonigrin inhibits SENP1 (IC50 of 0.518 µM) and reduces HIF1alpha. Streptonigrin increases p53 and Apoptosis. Streptonigrin shows antiviral activity against Rauscher murine leukemia virus. Streptonigrin has immunosuppressive effects. Streptonigrin has antitumor activity against osteosarcoma[1][2][3][4][5][6][7][8][9][10].
